Due to oversight on the part of the authors, G.I. Liou, A.B. El-Remessy, A.S. Ibrahim, R.B. Caldwell, Y.M. Khalifa, A. Gunes and J.J. Nussbaum., incomplete funding information was published in the review entitled “Cannabidiol as a Putative Novel Therapy for Diabetic Retinopathy: A Postulated Mechanism of Action as an Entry Point for Biomarker-Guided Clinical Development”, Current Pharmacogenomics and Personalized Medicine, September 2009, Vol. 7, No. 3, pp. 215–222.
The correct funding information should read as:
“This work was supported in part by grants from American Diabetes Association and Knights Templar Educational Foundation (GIL), Egyptian Culture and Education Bureau (ASI) and the US National Institutes of Health (R01-EY04618 and R01-EY11766) (RBC)”.